Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- ASKA, Senju Create Ceolia Pharma
October 11, 2010
- Fingolimod Approved in the US: Novartis
October 11, 2010
- CMIC Licenses Ecallantide for HAE from Dyax
October 11, 2010
- ARB + CCB Combination Micamlo for Hypertension: NBI, Astellas
October 4, 2010
- Covance to Jointly Operate Central Lab with BML in Japan
October 4, 2010
- Dosing of Taspoglutide Suspended in PIII Due to Adverse Reactions: Roche
October 4, 2010
- Japan's Second mTOR Inhibitor Torisel: Pfizer
October 4, 2010
- 46th EASD Annual Meeting Highlights GLP-1 Agonists, DPP-4 Inhibitors
October 4, 2010
- Kenporen Expects Record-High Deficit of ¥523.5 Bil. in FY2009
October 4, 2010
- Osteogenesis Promoter Forteo: Eli Lilly
October 4, 2010
- GLP-1 Agonist Liraglutide More Effective Than Sitagliptin:
October 4, 2010
- Sanofi-aventis Starts Multinational PIV ATLAS Study for Lantus
October 4, 2010
- Volibris for Oral Treatment of PAH: GSK
October 4, 2010
- Meta-Analysis Shows Greater Effects of GLP-1 Analogues on HbA1c and Weight
October 4, 2010
- Mylan Opens 24-Hour Customer Support Center
October 4, 2010
- Japan's 5th Biologic for RA Orencia: Bristol Myers
October 4, 2010
- Alogliptin Effectively Reduces HbA1c in Combination with Other Antidiabetic Agents
October 4, 2010
- JAOG Requests Public Funding for HTLV-1 Screening in Pregnancy
October 4, 2010
- Albumin-Bound Paclitaxel Abraxan: Taiho
October 4, 2010
- Lixisenatide Significantly Reduces HbA1c but Not Weight
October 4, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…